The European School of Oncology and Pfizer have started an initiative that aims to help prolong the lives of people with advanced breast cancer by 2025.

Rosetta Genomics and Meir Medical Center in Kfar Saba, Israel, will observe nonsmall cell lung cancer patients who were considered for treatment that would have used their immune systems to fight cancer.

Merck gave a number of scientific discussions, including Phase 3 data on ertugliflozin and information on Januvia, this month at the 77th Scientific Sessions of the American Diabetes Association.

Sanofi and Regeneron Pharmaceuticals Inc. recently received approval from the Food & Drug Administration (FDA) for its drug Kevzara to treat people with moderate to severe rheumatoid arthritis.

American Cancer Society (ACS) researchers tested prostate-specific antigen (PSA) patterns in men 50 years and older and found many still undergo PSA testing regardless of scientific recommendations.

In a recent report published in Neurotherapeutics, University of California, Los Angeles researchers said they developed a compound that helped assist with coordination and balance in mice with Parkinson’s disease.

University of California San Diego School of Medicine said it has agreed to a five-year partnership with Janssen Pharmaceuticals, a division of the Janssen Pharmaceutical Companies of Johnson & Johnson, to research treatments for metabolic diseases.

Pfizer said it prepared findings from studies of 13 kinds of cancers for the recent American Society of Clinical Oncology (ASCO) annual meeting.

Fungi in the intestines may play a role in developing alcohol-caused liver disease, including steatosis and cirrhosis according to a study funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA).

Pfizer said its drug tafamidis, an investigational treatment for transthyretin cardiomyopathy (TTR-CM), a rare, fata disease linked to progressive heart failure, has been granted U.S. Food and Drug Administration (FDA) fast track designation.

The Trump administration is drafting a final executive order that could drastically change how U.S. drug companies and patients will interact with the international community.

Protection from both strokes and heart attacks – two of the most prevalent causes of death among women – may last a lot longer than previously thought for mothers who breastfeed their babies, a report from the American Heart Association (AHA) said.

Regulators in the European Union are set to consider whether Mimpara, a drug from Amgen used to treat parathyroid disease, can be used in children as young as 3 who also suffer from kidney failure.

AstraZeneca said in a release its hormone-therapy breast cancer drug Faslodex (fulvestrant) has been authorized for a second look by European Commission (EC) regulators.

Promising results of a clinical trial assessing AbbVie's Venclyxto leukemia drug were shared at the European Hematology Association's recent 22nd annual congress in Madrid.

Astellas said preliminary results from an ongoing clinical trial of its potential leukemia drug gilteritinib show it may be a long-awaited treatment option for certain patients with a acute myeloid leukemia.

AbbVie said a subcommittee of the European Medicines Agency has recommended marketing authorization approval of hepatitis C drug Maviret, a step toward broadening the available treatments for patients with liver and kidney disease in approximately 30 European and Scandinavian countries.

A complication of open-heart surgery that keeps patients from absorbing essential protein through their intestinal walls has been solved, according to a study by scientists at Children’s Hospital of Philadelphia and Penn Medicine in Philadelphia.

Researchers at Northwestern Medicine in Chicago, aided by $3.3 million in funding from the National Institutes of Health, have launched a clinical trial to unlock the secrets of a widely seen inherited heart defect known as bicuspid aortic valve (BAV).

The first patient tests for a cancer drug that pinpoints many different types of cancer are underway by San Francisco-based biopharmaceutical company CytomX Therapeutics Inc.